Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Autor: Frederick L Locke, Stephan A Grupp, Elizabeth J Shpall, Sattva S Neelapu, Michael R Bishop, Marcela V Maus, Jorg Dietrich, Daniel W Lee, Matthew J Frigault, Terry J Fry, Sara Alexander, Jennifer N Brudno, Colleen Callahan, Marco L Davila, Claudia Diamonte, Julie C Fitzgerald, Jennifer L Holter-Chakrabarty, Krishna V Komanduri, Shannon L Maude, Philip L McCarthy, Elena Mead, Tomas G Neilan, Bianca D Santomasso, David T Teachey, Cameron J Turtle, Tom Whitehead

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disea

Externí odkaz: https://doaj.org/article/d61d44366994471cbc391339ac6fd898

Data from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Autor: Michel Sadelain, David R. Jones, Renier J. Brentjens, Charles M. Rudin, Mithat Gönen, William D. Travis, Xiuyan Wang, Brigitte Senechal, Devanjan Sikder, Shanu Modi, Jennifer L. Sauter, Claudia Diamonte, Alain Vincent, Erin McGee, Daniel Ngai, Jose A. Araujo Filho, Bobby Daly, Kay See Tan, Rocio Perez-Johnston, John Pineda, Elizabeth Halton, Navin K. Chintala, Waseem Cheema, Amy Zhu, Roisin E. O'Cearbhaill, Valerie W. Rusch, Stephen B. Solomon, Isabelle Rivière, Marjorie G. Zauderer, Prasad S. Adusumilli

Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac14f81f293bc0662bda23690f6d38f
https://doi.org/10.1158/2159-8290.c.6549458.v1

Supplementary Material from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Autor: Michel Sadelain, David R. Jones, Renier J. Brentjens, Charles M. Rudin, Mithat Gönen, William D. Travis, Xiuyan Wang, Brigitte Senechal, Devanjan Sikder, Shanu Modi, Jennifer L. Sauter, Claudia Diamonte, Alain Vincent, Erin McGee, Daniel Ngai, Jose A. Araujo Filho, Bobby Daly, Kay See Tan, Rocio Perez-Johnston, John Pineda, Elizabeth Halton, Navin K. Chintala, Waseem Cheema, Amy Zhu, Roisin E. O'Cearbhaill, Valerie W. Rusch, Stephen B. Solomon, Isabelle Rivière, Marjorie G. Zauderer, Prasad S. Adusumilli

Supplemental Material

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19730e3240818ead70d0835e6f42b4c5
https://doi.org/10.1158/2159-8290.22540712.v1

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Autor: Brigitte Senechal, Mark B. Geyer, Marco L. Davila, Kevin J. Curran, Mithat Gonen, Mikhail Roshal, Isabelle Riviere, Michel Sadelain, Peter Maslak, Jessica Flynn, Kitsada Wudhikarn, Claudia Diamonte, Renier J. Brentjens, Jae H. Park, Xiuyan Wang, Elizabeth Halton

Publikováno v: Blood

CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8ff1d113f01629e7b4b42373a8056ce
https://doi.org/10.1182/blood.2020009515

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Autor: Matthew J. Frigault, Philip L. McCarthy, Jorg Dietrich, Shannon L. Maude, David T. Teachey, Stephan A. Grupp, Tom Whitehead, Sara Alexander, Sattva S. Neelapu, Terry J. Fry, Tomas G. Neilan, Marco L. Davila, Elena Mead, Jennifer N. Brudno, Jennifer Holter-Chakrabarty, Claudia Diamonte, Frederick L. Locke, Daniel W. Lee, Bianca Santomasso, Elizabeth J. Shpall, Julie C. Fitzgerald, Krishna V. Komanduri, Marcela V. Maus, Colleen Callahan, Michael R. Bishop, Cameron J. Turtle

Publikováno v: Journal for immunotherapy of cancer, vol 8, iss 2
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78826d8095d2b25719dcc661bc8a0aef
https://escholarship.org/uc/item/0fj5p33n